Patents by Inventor Qinwei Wang

Qinwei Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11945975
    Abstract: Provided are a water-based adhesive and a preparation method thereof, and its use in an anode of a lithium battery. The method for preparing a water-based adhesive includes mixing a surfactant, acrylic acid, acrylonitrile, acrylamide and water to obtain a mixture system; heating the mixture system to a polymerization temperature to obtain a heated mixture system; adding an initiator into the heated mixture system and subjecting a resulting system to polymerization to obtain a linear polymer; adding a cross-linking agent into the linear polymer and subjecting a resulting mixture to cross-linking reaction to obtain a cross-linking system; cooling the cross-linking system after the cross-linking reaction is completed to obtain a cooled cross-linking system; and adjusting a pH of the cooled cross-linking system to 6-7 to obtain the water-based adhesive.
    Type: Grant
    Filed: November 2, 2023
    Date of Patent: April 2, 2024
    Assignee: QIHE LEAHOU CHEMICAL CO., LTD.
    Inventors: Lianxiang Feng, Feng Hai, Mingtao Li, Qinwei Zhou, Shuguang Qu, Shunping Wang
  • Patent number: 10800760
    Abstract: The present invention relates to the use of substituted pyrazole derivatives to modulate tropomyosin-related kinase (Trk) family protein kinase, and the use of the substituted pyrazole derivatives for the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: October 13, 2020
    Assignee: NANTBIO, INC.
    Inventors: Chunlin Tao, Qinwei Wang, Sharif Asad, Paul Weingarten, Sherry Ci
  • Patent number: 10766879
    Abstract: The present invention provides antitumor agents comprising substituted pyrimidine derivatives and pharmaceutically-acceptable formulations thereof, methods for making novel compounds and methods for using the compounds. The compounds and compositions in accordance with the invention have utility in treatment of a variety of diseases and have kinase inhibitory activities.
    Type: Grant
    Filed: February 27, 2015
    Date of Patent: September 8, 2020
    Assignee: NANTBIOSCIENCE, INC.
    Inventors: Chunlin Tao, Qinwei Wang, Laxman Nallan, David Ho, Tulay Polat, Forrest Arp, Paul Weingarten
  • Patent number: 10738033
    Abstract: The present invention relates to the use of substituted pyrimidine derivatives to modulate tropomyosin-related kinase (Trk) family protein kinase, and the use of the substituted pyrimidine derivatives for the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA. The present invention also provides compounds of the formula: as defined herein.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: August 11, 2020
    Assignee: NANTBIO, INC.
    Inventors: Chunlin Tao, Qinwei Wang, Sharif Asad, Paul Weingarten, Sherry Ci
  • Patent number: 10392397
    Abstract: Pharmaceutical compounds, compositions, and methods are presented in which various heterocyclic thiosemicarbazone derivatives are prepared. Contemplated compounds will be suitable to inhibit or reduce cellular growth or proliferation and are thus beneficial in the manufacture of drugs to treat neoplastic diseases.
    Type: Grant
    Filed: August 8, 2016
    Date of Patent: August 27, 2019
    Assignees: NantBio, Inc., Nant Holdings IP, LLC
    Inventors: Chunlin Tao, Qinwei Wang, Patrick Soon-Shiong
  • Patent number: 10344026
    Abstract: Compounds and compositions are presented that inhibit K-Ras, and especially mutant K-Ras. Certain compounds preferentially or even selectively inhibit specific forms of mutant K-Ras, and particularly the G12D mutant form.
    Type: Grant
    Filed: January 18, 2018
    Date of Patent: July 9, 2019
    Assignee: NantBio, Inc.
    Inventors: Chunlin Tao, Laxman Nallan, David G. Ho, Qinwei Wang, Paul Weingarten, Anna B. Juncker-Jensen
  • Patent number: 10245261
    Abstract: The present invention relates generally to the use of compounds to treat a variety of disorders, diseases and pathologic conditions and more specifically to the use of substituted indol-5-ol derivatives to modulate protein kinases and for treating protein kinase-mediated diseases.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: April 2, 2019
    Assignee: NantBio, Inc.
    Inventors: Chunlin Tao, Qinwei Wang, David Ho, Tulay Polat, Laxman Nallan, Patrick Soon-Shiong
  • Patent number: 10160749
    Abstract: The present invention relates generally to the use of compounds to treat a variety of disorders, diseases and pathologic conditions and more specifically to the use of substituted indol-5-ol derivatives to modulate protein kinases and for treating protein kinase-mediated diseases.
    Type: Grant
    Filed: October 4, 2016
    Date of Patent: December 25, 2018
    Assignee: NantBio, Inc.
    Inventors: Chunlin Tao, Qinwei Wang, David Ho, Tulay Polat, Laxman Nallan, Patrick Soon-Shiong
  • Publication number: 20180346450
    Abstract: The present invention relates to the use of substituted pyrazole derivatives to modulate tropomyosin-related kinase (Trk) family protein kinase, and the use of the substituted pyrazole derivatives for the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.
    Type: Application
    Filed: May 30, 2018
    Publication date: December 6, 2018
    Inventors: Chunlin Tao, Qinwei Wang, Sharif Asad, Paul Weingarten, Sherry Ci
  • Publication number: 20180346451
    Abstract: The present invention relates to the use of substituted pyrimidine derivatives to modulate tropomyosin-related kinase (Trk) family protein kinase, and the use of the substituted pyrimidine derivatives for the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.
    Type: Application
    Filed: May 30, 2018
    Publication date: December 6, 2018
    Inventors: Chunlin Tao, Qinwei Wang, Sharif Asad, Paul Weingarten, Sherry Ci
  • Publication number: 20180318473
    Abstract: The invention provides a medical device comprising a hydrophobic analog of a medicament known to inhibit cell proliferation and migration. The invention also provides a method of treating a narrowing in a body passageway comprising placing an implantable medical device comprising a hydrophobic analog of a medicament known to inhibit cell proliferation and migration. The medicaments can be incorporated within or coated on the device. The invention further provides hydrophobic analogs of medicaments known to inhibit cell proliferation and migration.
    Type: Application
    Filed: July 2, 2018
    Publication date: November 8, 2018
    Inventors: Neil P. Desai, Chunlin Tao, Cheng Zhi Yu, Qinwei Wang, Patrick Soon-Shiong
  • Publication number: 20180215734
    Abstract: The present invention provides kinase inhibitors with anti-proliferative activity comprising substituted pyrimidine derivatives and pharmaceutically-acceptable formulations thereof. In addition, the invention provides methods for making novel compounds and methods for using the compounds.
    Type: Application
    Filed: February 29, 2016
    Publication date: August 2, 2018
    Inventors: Chunlin Tao, Qinwei Wang, Laxman Nallan, David Ho, Tulay Polat, Forrest Arp, Paul Weingarten
  • Publication number: 20180208603
    Abstract: Pharmaceutical compounds, compositions, and methods are presented in which various heterocyclic thiosemicarbazone derivatives are prepared. Contemplated compounds will be suitable to inhibit or reduce cellular growth or proliferation and are thus beneficial in the manufacture of drugs to treat neoplastic diseases.
    Type: Application
    Filed: August 8, 2016
    Publication date: July 26, 2018
    Inventors: Chunlin TAO, Qinwei WANG, Patrick SOON-SHIONG
  • Publication number: 20180201610
    Abstract: Compounds and compositions are presented that inhibit K-Ras, and especially mutant K-Ras. Certain compounds preferentially or even selectively inhibit specific forms of mutant K-Ras, and particularly the G12D mutant form.
    Type: Application
    Filed: January 18, 2018
    Publication date: July 19, 2018
    Inventors: Chunlin Tao, Laxman Nallan, David G. Ho, Qinwei Wang, Paul Weingarten, Anna B. Juncker-Jensen
  • Publication number: 20180155327
    Abstract: The present invention provides antitumor agents comprising substituted pyrimidine derivatives and pharmaceutically-acceptable formulations thereof, methods for making novel compounds and methods for using the compounds. The compounds and compositions in accordance with the invention have utility in treatment of a variety of diseases and have kinase inhibitory activities.
    Type: Application
    Filed: February 27, 2015
    Publication date: June 7, 2018
    Inventors: Chunlin Tao, Qinwei Wang, Laxman Nallan, David Ho, Tulay Polat, Forrest Arp, Paul Weingarten
  • Publication number: 20170203012
    Abstract: The invention provides a medical device comprising a hydrophobic analog of a medicament known to inhibit cell proliferation and migration. The invention also provides a method of treating a narrowing in a body passageway comprising placing an implantable medical device comprising a hydrophobic analog of a medicament known to inhibit cell proliferation and migration. The medicaments can be incorporated within or coated on the device. The invention further provides hydrophobic analogs of medicaments known to inhibit cell proliferation and migration.
    Type: Application
    Filed: March 31, 2017
    Publication date: July 20, 2017
    Inventors: Neil P. Desai, Chunlin Tao, Cheng Zhi Yu, Qinwei Wang, Patrick Soon-Shiong
  • Publication number: 20170088544
    Abstract: The present invention relates generally to the use of compounds to treat a variety of disorders, diseases and pathologic conditions and more specifically to the use of substituted indol-5-ol derivatives to modulate protein kinases and for treating protein kinase-mediated diseases.
    Type: Application
    Filed: October 4, 2016
    Publication date: March 30, 2017
    Inventors: Chunlin Tao, Qinwei Wang, David Ho, Tulay Polat, Laxman Nallan, Patrick Soon-Shiong
  • Patent number: 9458137
    Abstract: The present invention relates generally to the use of compounds to treat a variety of disorders, diseases and pathologic conditions and more specifically to the use of substituted indol-5-ol derivatives to modulate protein kinases and for treating protein kinase-mediated diseases.
    Type: Grant
    Filed: November 5, 2013
    Date of Patent: October 4, 2016
    Assignee: NantBioScience, Inc.
    Inventors: Chunlin Tao, Qinwei Wang, David Ho, Tulay Polat, Laxman Nallan, Patrick Soon-Shiong
  • Patent number: 9409903
    Abstract: The invention provides triazine compounds and methods of their use to modulate protein kinases and to treat diseases mediated by said protein kinases.
    Type: Grant
    Filed: November 3, 2014
    Date of Patent: August 9, 2016
    Assignee: NantBioScience, Inc.
    Inventors: Chunlin Tao, Qinwei Wang, David Ho, Laxman Nallan, Tulay Polat, Xiaowen Sun, Neil Desai
  • Publication number: 20150291564
    Abstract: The present invention relates generally to the use of compounds to treat a variety of disorders, diseases and pathologic conditions and more specifically to the use of substituted indol-5-ol derivatives to modulate protein kinases and for treating protein kinase-mediated diseases.
    Type: Application
    Filed: November 5, 2013
    Publication date: October 15, 2015
    Applicant: NantBioScience, Inc.
    Inventors: Chunlin Tao, Qinwei Wang, David Ho, Tulay Polat, Laxman Nallan, Patrick Soon-Shiong